...
首页> 外文期刊>International Journal of Pharmaceutical Sciences and Research >HISTAMINE SUBTYPE 3 RECEPTOR ANTAGONISTS: CURRENT STATUS WITH FUTURE PROSPECTS IN DRUG DISCOVERY AND DRUG DEVELOPMENT
【24h】

HISTAMINE SUBTYPE 3 RECEPTOR ANTAGONISTS: CURRENT STATUS WITH FUTURE PROSPECTS IN DRUG DISCOVERY AND DRUG DEVELOPMENT

机译:组胺亚型3受体拮抗剂:药物发现和药物开发的近期前景

获取原文
           

摘要

The histamine H3 receptor is an G protein-coupled receptor that regulates neurotransmission in the central nervous system and plays a major role in cognitive and homeostatic functions. The third histamine receptor was discovered in 1983 by a traditional pharmacological approach, consisting of assessing the inhibitory effect of histamine on its own release from depolarized rat brain slices. Histamine H3 receptors are found mostly in central nervous system also to some extent in peripheral tissues and involved in the regulation of release of various neurotransmitters in brain. They have been implicated in diverse potential therapeutic applications such as sleep wake disorders, attention-deficient hyperactivity disorder, epilepsy, cognitive impairment and obesity. This review is aimed to provide an overview of marketed preparations and also experimental H3 receptor antagonists under pipeline of drug discovery and development
机译:组胺H3受体是一种G蛋白偶联受体,可调节中枢神经系统的神经传递,并在认知和体内平衡功能中起主要作用。第三种组胺受体是通过传统药理学方法于1983年发现的,该方法包括评估组胺对去极化大鼠脑片自身释放的抑制作用。组胺H3受体主要存在于中枢神经系统中,在某种程度上还存在于周围组织中,并参与调节大脑中各种神经递质的释放。它们与多种潜在的治疗应用有关,例如睡眠唤醒障碍,注意力缺陷多动障碍,癫痫,认知障碍和肥胖症。这篇综述旨在概述市售制剂以及药物发现和开发中的实验性H3受体拮抗剂

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号